Diagnostic and therapeutic challenges for patients with ANCA-associated vasculitides at the time of COVID-19. Response to: 'Rituximab for granulomatosis with polyangiitis in the pandemic of COVID-19: lessons from a case with severe pneumonia' by Guilpain et al

Ann Rheum Dis. 2021 Jan;80(1):e11. doi: 10.1136/annrheumdis-2020-217555. Epub 2020 Apr 30.
No abstract available

Keywords: autoimmunity; rituximab; systemic vasculitis.

Publication types

  • Comment

MeSH terms

  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis* / drug therapy
  • COVID-19*
  • Granulomatosis with Polyangiitis* / drug therapy
  • Humans
  • Pandemics
  • Rituximab / therapeutic use
  • SARS-CoV-2

Substances

  • Rituximab